CATT of course tested ranibizumab (Lucentis) as the control against bevacizumab (Avastin) and not aflibercept (Eylea) against bevacizumab (Lucentis).
Apologies. I was too late to edit my above post.
- Forums
- ASX - By Stock
- Ann: Opthea to Host Key Opinion Leader Event on April 3, 2024
CATT of course tested ranibizumab (Lucentis) as the control...
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OPT (ASX) to my watchlist
|
|||||
Last
40.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $498.5M |
Open | High | Low | Value | Volume |
40.5¢ | 42.5¢ | 38.8¢ | $1.099M | 2.714M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 266232 | 40.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
41.5¢ | 217540 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1197 | 0.410 |
15 | 196112 | 0.405 |
10 | 189420 | 0.400 |
6 | 177531 | 0.395 |
11 | 139491 | 0.390 |
Price($) | Vol. | No. |
---|---|---|
0.415 | 150000 | 2 |
0.420 | 109119 | 3 |
0.425 | 20000 | 1 |
0.440 | 13031 | 2 |
0.445 | 1 | 1 |
Last trade - 16.10pm 25/07/2024 (20 minute delay) ? |
Featured News
OPT (ASX) Chart |